Giancarlo Logroscino, MD, PhD, Università degli Studi di Bari, Bari, Italy, discusses the use of biomarkers for Alzheimer’s disease (AD) in the clinic. Biomarkers can be used to diagnose AD by evaluating the expression of disease pathology. However, currently biomarkers are not at a point in which they can be translated to clinical or preclinical practice. This interview took place during the Virtual World Congress on Controversies in Neurology (CONy) 2020.
Giancarlo Logroscino is associate editor of the Journal Neuroepidemiology, Karger and PI or co-PI of several grants, mainly from national agencies.